Y-SIRT, were analyzed, yielding 48 tumor and 31 normal liver contours. We validated the accuracy of absorbed doses calculated by a commercial software against those calculated using Monte Carlo-based radiation transport. The software package was used to analyze the following definitions of SPECT volume of interest used for 90 Y-SPECT self-calibration: (a) SPECT field-of-view (FOV), (b) chest-abdomen contour, (c) total liver contour, (d) total liver contour expanded by 5 mm, and (e) total liver contour contracted by 5 mm. Linear correlation and BlandAltman analysis were performed for tumor and normal liver tissue absorbed dose volume histogram metrics between the five different approaches for 90 Y-SPECT self-calibration. Results: The mean dose calculated using the commercial software was within 3% of Monte Carlo for tumors and normal liver tissues. The tumor mean dose calculated using the chest-abdomen calibration was within 2% of that calculated using the SPECT FOV, whereas the doses calculated using the total liver contour, expanded total liver contour, and contracted total liver contour were within 68%, 47%, and 107%, respectively, of doses calculated using the SPECT FOV. The normal liver tissue mean dose calculated using the chest-abdomen contour was within 1.3% of that calculated using the SPECT FOV, whereas the doses calculated using the total liver contour, expanded total liver contour, and contracted total liver contour were within 73%, 50%, and 114%, respectively, of doses calculated using the SPECT FOV. Conclusions: The mean error of < 3% for commercial software can be considered clinically acceptable for 90 Y-SIRT dosimetry. Absorbed dose quantification using 90 Y-SPECT self-calibration with the chest-abdomen contour was equivalent to that calculated using the SPECT FOV, but self-calibration with the total liver contour yielded substantially higher (~70%) dose values. The large biases revealed by our study suggest that consistent absorbed dose calculation approaches are essential when comparing 90 Y-SIRT dosimetry between different clinical studies.
INTRODUCTION
Y is a pure beta emitter with a half-life of 64.1 h and maximum energy of 2.23 MeV. The energetic beta emission from 90 Y decay delivers high levels of radiation absorbed dose at sites of microsphere deposition while sparing normal liver tissue more than 5-10 mm away.
5 90 Y-SIRT efficacy depends on the delivery of a tumoricidal absorbed radiation dose to the tumors while maintaining safe levels of absorbed radiation dose to normal liver tissue, and therefore, patient-specific treatment planning is performed. As part of 90 Y-SIRT planning, 99m Tc-macroaggregated albumin (MAA) planar scintigraphy is performed to determine the lung shunt fraction for prevention of radiation pneumonitis. In addition, Tc-MAA single-photon emission computed tomography (SPECT)/computed tomography (CT) may also be performed to assess the perfused liver volumes during SIRT.
Knowledge of the absorbed dose delivered to tumors and normal liver tissue is essential to improve the efficacy of 90 Y-SIRT. Although 99m Tc-MAA SPECT/CT images could, in principle, be used for predictive dosimetry, the highly variable and inconsistent concordance observed between MAA and 90 Y-microsphere distributions poses a major challenge. 6, 7 The discrepancies observed in the in vivo distribution between planning 90 Y-SIRT. 8 Furthermore, 90 Y SPECT/CT also facilitates dosimetry at the voxel level that allows for investigations into the volume distribution of absorbed doses in tumors and normal liver tissue. [9] [10] [11] A number of approaches have been described in the literature for generation and quantitation of 90 Y bremsstrahlung SPECT/CT, as described in a recent review article. 12 Some of the approaches for 90 Y SPECT quantitation include Monte Carlo-based modeling of SPECT corrections and reconstructions 13, 14 to multiple energy window-based scatter compensations. 10 90 Y-activity administrations are based on the device package insert dosimetry that recommend adjustment of the 90 Yactivity based on the predicted 90 Y-microsphere lung shunt or dose using 99m Tc-MAA planar scintigraphy images. 15, 16 In a clinical study involving 76 patients, the mean lung dose determined using 99m Tc-MAA planar geometric-mean images was reported to, on average, overestimate by 380% the mean lung dose using 99m Tc-MAA SPECT/CT (that incorporated scatter and attenuation correction). 17 In a separate study of 14 patients, the overestimation of mean lung dose with 99m Tc-MAA planar images was reported to be around 220% when compared to 99m Tc-MAA SPECT/CT, and by a factor of 275 when compared to the mean lung dose reported by post-therapy SPECT/CT scans. 18 Therefore, the lung shunt fraction determined from 99m Tc-MAA geometric-mean images are expected to exceedingly overestimate the true lung shunt fraction.
The net 90 Y-activity administered during SIRT can be determined with an accuracy better than 95% (especially for glass-microspheres). In SIRT, the 90 Y-activity is deposited predominantly in the liver with perhaps a very small degree of shunting to the lungs. The typical axial extend of SPECT scans are~40 cm; therefore, in addition to the entire liver, a large fraction of the lung volume is also contained within the SPECT field-of-view (FOV) (see Fig. 1 90 Y SPECT self-calibration and extract voxellevel absorbed doses, we used a commercially available software package. However, the accuracy of the software package has not been validated; therefore, the secondary objective of the study was to investigate the accuracy of the algorithm used for dosimetry by the commercial software. We then investigated the effects of three different approaches for 90 Y-SPECT self-calibration on the quantification of absorbed doses for tumors and normal liver tissues following 90 Y-SIRT.
MATERIALS AND METHODS

2.A. Clinical data
90 Y bremsstrahlung SPECT/CT images of 31 patients with hepatocellular carcinoma, collected following 90 Y-glassmicrosphere (TheraSphere, BTG International, London, UK) SIRT, were arbitrarily selected from our patient database for the current study. There was no strict patient selection criteria applied for data used in the study because the comparisons between dosimetry models were based on matched inputs between the various approaches and therefore independent of the specifics of the patient population.
90 Y-SIRT procedures were done as a part of the standard of care and all data were retrospectively analyzed under a protocol approved by the Institutional Review Board. Administered 90 Y activity was based on the device package insert dosimetry. 15 Administered activity was decreased if mean lung dose was predicted to be over 30 Gy based on each patient's lung shunt fraction from 99m Tc-MAA geometric-mean images. The median (range) of lung shunt fractions was 6.78% (2.1% to 22.7%). The median (range) of administered activity was 3.215 (1.64 to 8.03) GBq. The median (range) of mean dose to treated liver volume was 110 (80 to 135) Gy. Diagnostic CT or magnetic resonance images were manually registered to the SPECT/CT to aid in tumor delineation. A single interventional radiologist segmented the total liver and tumors for all patients using the co-registered CT and/or magnetic resonance images. Normal liver VOIs were generated by subtracting the tumor contours from the total liver contour. Tumor selection for dosimetry was based on the following criteria: a minimum tumor diameter of 25 mm and a maximum of three tumors per patient. A total of 48 tumor contours and 31 normal liver contours were used in the study.
Details on the acquisition and reconstruction parameters of the post-SIRT 90 Y bremsstrahlung SPECT/CT images of the patients have been previously reported in Siman et al. 10 Briefly, the 90 Y SPECT/CT scans were acquired on a Symbia T6 or T16 (Siemens Medical Solutions, Hoffman Estates, IL, USA) with medium-energy low-penetration collimation. SPECT data were acquired with a 90-125 keV imaging window and a 310-410 keV scatter window for 128 views over 360°with 28 s/view. A three-dimensional (3D) ordered-subset expectation maximization (Flash3D, Siemens Medical Solutions) SPECT reconstruction was performed using 8 iterations and 16 subsets with geometric collimator response modeling, CT-based attenuation correction using effective energy of the imaging window, dual energy window-based scatter correction, and a 9.6 mm FWHM Gaussian postfiltering. 10 The reconstructed isotropic voxel size was 4.8 mm.
2.B. SPECT self-calibration
90 Y SPECT images (counts/ml) for each patient were converted to activity concentration (Bq/ml) using SPECT selfcalibration. The self-calibration approach used to determine the 90 Y activity concentration from 90 Y SPECT/CT images following 90 Y-SIRT has been previously described. [9] [10] [11] Briefly, the counts in each reconstructed SPECT voxel (counts/ml) were first normalized by the total counts in a prescribed SPECT FOV and then multiplied by the net administered 90 Y-microsphere activity to compute the 90 Y activity concentration in that SPECT voxel (Bq/ml). The different approaches for 90 Y SPECT self-calibration stem from different definitions of the SPECT VOI used to determine the total SPECT counts associated with the 90 Y activity. Five different SPECT VOI definitions were explored in this work; they are described in more detail in Section 2.D.2.
Quantitative 90 Y SPECT/CT images of patients after 90 Y-SIRT can be reliably generated using self-calibration because the net 90 Y-activity within the liver or the SPECT FOV can be determined with high accuracy (> 95%). We contend, as discussed earlier, that any correction of the net administered 
2.C. Voxel dosimetry models
The two different dosimetry algorithms investigated in this work for converting activity concentration (Bq/ml) from quantitative 90 Y SPECT/CT images into absorbed dose maps (Gy) at the voxel level are described next.
2.C.1. Monte Carlo dosimetry
The SPECT VOI used for 90 Y SPECT self-calibration is the total counts in the entire SPECT FOV. The 90 Y activity concentration in each 90 Y SPECT/CT voxel was converted into three-dimensional voxel level absorbed dose (Gy) using Monte Carlo-based radiation transport of the beta emission and all secondary photon and electron transport. Monte Carlo calculations were performed with the EGSnrc 19 user code DOSXYZnrc. 20 The validity and accuracy of the EGSnrc DOSXYZ Monte Carlo software implementation used in the current study has been reported by Mikell et al. 21 
2.C.2. 90Y-SurePlan dosimetry
90 Y SPECT/CT images of patients used for Monte Carlo dosimetry were also input into SurePlan LiverY90 dosimetry toolkit (version 6.6.6; MIM Software, Cleveland, OH, USA), henceforth referred to as 90Y-SurePlan. The SPECT self-calibration approach is also used in 90Y-SurePlan for quantifying the 90 Y SPECT activity concentration; however, in this approach, the SPECT VOI used for 90 Y SPECT self-calibration is the total counts in the chest-abdomen VOI that includes the liver and most of the thorax except for the apex. The chest-abdomen VOI in 90Y-SurePlan is automatically generated by threshold-based segmentation of the CT images (associated with SPECT/CT), taking advantage of the distinct discontinuity in the CT number (HU) across the skin interface between soft tissue and air outside the body. In addition, 90Y-SurePlan uses the local dose deposition algorithm 9 to compute absorbed dose at the voxel level. The equivalence between local dose deposition and Monte Carlo radiation transport for 90 Y-based absorbed dose deposition in soft tissue has been reported in Mikell et al. 9 
2.D. Data analysis
The data analysis for this work used a two-step approach. We first validated the implementation of the 90Y-SurePlan dose calculation algorithm against the gold-standard Monte Carlo algorithm using identical inputs. Once validated, the 90Y-SurePlan software package was used to investigate the impact of five different definitions of SPECT VOI used for 90 Y SPECT self-calibration. Specific details of the data analysis are described next. Statistical analysis of the data generated is described in the subsequent section.
2.D.1. Evaluation of the fundamental 90Y-SurePlan dose calculation algorithm
The accuracy of 90Y-SurePlan was first benchmarked against the well-established Monte Carlo-based radiation transport algorithm for voxel dosimetry by performing a quantitative comparison of the dose volume histograms (DVH) generated using the two algorithms on matched volumes of interest (VOIs) for tumors and normal liver tissues. Comparison of the 90Y-SurePlan and Monte Carlo algorithms requires the inputs into both algorithms to be (ideally) identical or at least as close as possible. The following identical inputs were used for both algorithms: 90 Y SPECT/CT data, tumor and normal liver contours, and administered 90 Y-microsphere activity. Furthermore, counts from the SPECT FOV was used to convert SPECT counts/voxel into 90 Y Bq/voxel for both algorithms; requiring a modification of the 90Y-SurePlan workflow to use of the entire SPECT FOV. Three-dimensional voxel-level absorbed dose maps (in Gy) were generated with both 90Y-SurePlan and Monte Carlo algorithms.
Absorbed DVHs, which plot the threshold absorbed dose (abscissa) against the fractional VOI with absorbed dose greater than or equal to the threshold (ordinate), were generated for all tumor and normal liver VOIs. The mean dose, D70, D50, and D20 (where D# is defined as the minimum absorbed dose that covers #% of the VOI) were extracted from the tumor and normal liver DVHs. In addition, V30
(where V# is defined as the fractional VOI with absorbed dose greater than # Gy) was extracted from the normal liver DVHs. The aforementioned DVH metrics were computed from absorbed dose maps generated using both Monte Carlo and 90Y-SurePlan dosimetry methods.
2.D.2. Comparing the effect of different calibration VOIs on absorbed dose calculation
This evaluation was performed to compare absorbed dose estimates when using different approaches for 90 Y SPECT self-calibration, which in turn originates from different definitions of SPECT VOI to determine the total SPECT counts associated with the 90 Y activity. The 90Y-SurePlan software package was used to investigate the impact of five different definitions of SPECT VOI used for 90 Y SPECT self-calibration because the 90Y-SurePlan workflow can be edited in a straightforward manner to associate any VOI for SPECT quantification. As observed in phantom scans, it may well be the case that most of the counts outside of the liver observed in 90 Y SPECT images arise owing to imperfections in SPECT reconstruction and from the challenges associated with scatter correction of 90 Y bremsstrahlung emission. Therefore, the case where the total liver VOI (based on CT) was used for 90 Y SPECT self-calibration was also considered. Furthermore, two additional total liver VOIs were automatically generated -the total liver VOI was first expanded by 5 mm and then contracted by 5 mm -and used for 90 Y SPECT self-calibration to investigate the sensitivity of liver contouring to the absorbed dose calculation.
In summary, the following five different definitions of SPECT VOI used for 90 Y SPECT self-calibration were evaluated in the study (Fig. 1): (a) SPECT field-of-view, (b) chestabdomen contour, (c) total liver contour, (d) total liver contour expanded by 5 mm, and (e) total liver contour contracted by 5 mm.
2.E. Statistical analysis
The linear correlation coefficients (R 2 ) for tumor and normal liver tissue absorbed dose estimates using the different DVH metrics between the Monte Carlo and 90Y-SurePlan algorithms were computed, as described in Section 2.D.1. A Bland-Altman analysis was performed to further investigate the bias, computed as shown in Eq. (1), between the two dosimetry models. 22 
Bias in DVH
The difference data were tested for normality using the Shapiro-Wilk test, and the mean bias, standard deviation, and standard error for mean bias were calculated. These were then used to compute the 95% confidence interval (CI) for the mean bias and the 95% limits of agreement between the dosimetry methods.
Similar linear correlation and Bland-Altman analyses were performed for tumor and normal liver tissue absorbed dose estimates using the different DVH metrics among the five different approaches for 90 Y SPECT self-calibration, as described in Section 2.D.2. For the Bland-Altman analyses in these cases, the bias estimates in absorbed dose with the specific VOI for SPECT self-calibration under investigation were computed relative to the SPECT FOV, as shown in Eq. (2) below.
3. RESULTS
3.A. Evaluation of the fundamental 90Y-SurePlan dose calculation algorithm
Figures 2 and 3 shows an example of the various DVH metrics computed in the current study using both the Monte Carlo and the 90Y-SurePlan algorithm with SPECT FOV for tumors (mean dose, D70, D50, and D20) and normal liver tissue (mean dose, D70, D50, and D20). Figures 2(a) and 3(a) illustrate the observed correlations in DVH metrics for tumors and normal liver tissue between the Monte Carlo and the 90Y-SurePlan algorithms. The correlation plots show a strong linear relationship between the two methods, with R 2 > 0.97 for all DVH metrics in both tumors and normal liver tissues. The absorbed dose values to tumors calculated by the 90Y-SurePlan algorithm appear to be on average about 2%-4% higher than those calculated by the Monte Carlo algorithm, and for normal liver tissue, absorbed doses were 1%-4% lower on average with the 90Y-SurePlan algorithm than with the Monte Carlo algorithm.
Figures 2(b) and 3(b) show the Bland-Altman plots of percentage bias in mean dose to tumors (median bias of +2%) and normal liver tissue (median bias of À2%) calculated by 90Y-SurePlan compared with the Monte Carlo algorithm, along with the 95% limits of agreement. Shapiro-Wilk tests showed that the residuals for mean doses were normally distributed. The median error in the DVH metrics assessed for tumors was less than 3% with 95% limits of agreement between À15% and +21%, and the median error for normal liver tissue was less than 4% with 95% limits of agreement between À21% and +5%. Table I summarizes the results of Bland-Altman analysis for tumor and normal liver tissue DVH metrics when estimated using 90Y-SurePlan with SPECT FOV self-calibration and with the Monte Carlo algorithm. 
3.B. Comparison of the effects of different calibration VOIs on absorbed dose calculation
Mean dose estimates among the five different definitions of SPECT VOI used for 90 Y SPECT self-calibration were observed to be highly correlated (R 2 > 0.93, P < 0.01) for both tumors and normal liver tissues, as shown in Fig. 4 . Absorbed dose estimates using chest-abdomen contour selfcalibration (the 90Y-SurePlan default) demonstrated a very strong linear relationship (R 2 > 0.99) with absorbed dose estimates calculated using SPECT FOV self-calibration; the slope of the linear correlation for mean dose was close to unity (~1.02) for both tumors and normal liver tissues.
Although the absorbed doses determined using total liver contour self-calibration also showed a high linear correlation (R 2 > 0.94) with absorbed dose estimates calculated using SPECT FOV self-calibration, the differences in dose estimates were found to be substantially higher. The slopes of the linear correlation for mean dose to tumors and normal liver tissues were~1.7 with total liver contour self-calibration and ranged widely between 1.5 and 2.1 for the expanded and contracted total liver contour VOIs.
Summary statistics of the correlation analysis between SPECT FOV and chest-abdomen contour, total liver contour, and expanded and contracted total liver contour selfcalibration VOIs are shown in Table II. Table III summarizes the results of the Bland-Altman analysis of tumor and normal liver tissue mean doses for SPECT calibration with total liver contour and expanded and contracted total liver contour VOIs with reference to the calibration using SPECT FOV. Figure 5 shows the Bland-Altman graphs between SPECT FOV and total liver contour self-calibration approaches for mean dose to tumor and normal liver tissue calculated using different calibration approaches. The average biases for mean tumor and mean normal liver tissue doses using total liver contour compared with SPECT FOV self-calibration were 68% for tumors and 72% for normal liver tissues; the corresponding 95% limits of agreement were calculated to be 35-101% for tumors and 34-111% for normal liver tissues. The mean dose values to tumors and normal liver tissues computed using expanded total liver contour self-calibration were, on average, 47% for tumors and 50% for normal liver tissues. For contracted total liver contour self-calibration, the mean dose values were, on average, 106% for tumors and 113% for normal liver tissues.
When compared with SPECT calibration based on the total liver contour VOI, there was À12% to 21% variation in tumor dose owing to a AE 5 mm change in liver VOI delineation; the corresponding change to normal liver tissue dose was À14% to +24%. Validation of the 90Y-SurePlan software, as performed in the current study using Monte Carlo calculations as the gold standard, is a necessary first step to facilitate the use of 90Y-SurePlan for creating three-dimensional absorbed dose distributions. The mean error in mean tumor absorbed doses between the Monte Carlo and 90Y-SurePlan algorithms was determined to be less than 3% with a range of À9% to +14%. The mean error in dosimetry between different Monte Carlo packages has been reported to be around 5%. 11 Other sources of uncertainty for absorbed dose calculations following Y SPECT after 90 Y-SIRT; therefore, the goal of the current study was to quantify the differences in absorbed dose estimates based on various approaches for SPECT selfcalibration. In this work, three different definitions of SPECT VOI for 90 Y SPECT self-calibration were evaluated: (a) SPECT FOV, (b) chest-abdomen contour, and (c) total liver contour. We found that self-calibration using the SPECT FOV and chest-abdomen contours yielded very similar results, with mean differences in absorbed dose estimates of less than 2%. This agreement, which is in line with expectations, can be explained by the fact that only a very small fraction of 90 Y SPECT signal (counts) in the SPECT FOV is present outside the chest-abdomen contour (i.e., present in air).
More interestingly, the total liver contour VOI for self-calibration yielded substantially different dose values, with mean difference greater than 65%-75%, from those generated with chest-abdomen contour or SPECT FOV VOIs. These differences can be understood by realizing that a corresponding fraction of 90 Y SPECT signal (counts) in the SPECT FOV or chest-abdomen contour is present outside the total liver contour. The imperfections in the 90 Y scatter compensation technique that originate from challenges imposed by the 10 , albeit to varying degrees depending on the approaches used 12 . Therefore, the magnitude of differences between the total liver contour and SPECT FOV reported here is not universal and will vary for different SPECT reconstruction algorithms.
True extra-hepatic 90 Y deposition will result in a more focused 90 Y SPECT signal that can be distinguished from the diffused signal owing to scatter. Widespread availability of advanced imaging technologies in the interventional radiology suites, such as cone-beam CT, which has increased the sensitivity to detect extra-hepatic perfusion, has also increased the confidence that all delivered 90 Y is present only within the liver. These observations further justify the interpretation of 90 Y SPECT signal outside of the total liver contour as originating from scatter, lending credence to higher accuracy when using the total liver contour method compared with the SPECT FOV method for SPECT self-calibration.
The sensitivity of the total liver contour method in the absorbed dose calculation was assessed by recalculating the absorbed dose estimates with the total liver VOI expanded by 5 mm and contracted by 5 mm. We found that mean dose values using SPECT total liver contour calibration demonstrated a high dependence on the exact delineation of the total liver contour. Mean absorbed tumor dose values for self-calibration with the total liver contours expanded by 5 mm and contracted by 5 mm were, on an average, À12% and +21%, respectively, compared with the values estimated using the total liver calibration. The mean absorbed normal liver dose values for total liver contours expanded by 5 mm expanded and contracted by 5 mm were, on average, À14% and +24%, respectively, compared with the values estimated using the total liver calibration.
SPECT quantification using FOV for self-calibration has the advantage of not having any user dependence on SPECT calibration via the need for contouring of the total liver. However, this quantification method has the disadvantage that the inclusion of signal present outside of the liver in the calibration may lead to an underestimation of the true absorbed dose, i.e., less accurate but more precise. In contrast, SPECT quantification using the total liver contour for self-calibration has the advantage of providing more accurate absorbed dose estimates, but with the disadvantage that the absorbed dose values are highly sensitive to the manual delineation of the liver contour; i.e., more accurate but less precise.
To the best of our knowledge, this is the first study to report on the bias and variability in absorbed dose quantification due to the various approaches that can be used for selfcalibration of 90 Y SPECT after 90 Y-SIRT. The large biases and high levels of variability in absorbed dose quantification for tumors and normal livers between different dosimetry models such as MIRD, Partition Model, and Voxel dosimetry in relation to 90 Y-SIRT have been previously reported. 9 We believe that the results reported here will be crucial in establishing guidelines for 90 Y SPECT calibration and in the interpretation of absorbed doses based on 90 Y SPECT from different clinical studies.
CONCLUSIONS
The 90Y-SurePlan algorithm yielded a mean error of < 3% relative to the Monte Carlo algorithm, which can be considered clinically acceptable for 90 Y-SIRT dosimetry. Absorbed dose quantification using 90 Y SPECT self-calibration with the chest-abdomen contour was equivalent to using the SPECT FOV but self-calibration with the total liver contour yielded substantially higher (~70%) dose values. SPECT quantification using the SPECT FOV for self-calibration is less accurate but more precise (given that it is not dependent on manual contouring), whereas SPECT quantification using the total liver contour for self-calibration is more accurate but less precise (owing to the sensitivity to manual contouring of the liver). Liver contour variability by 1 pixel (5mm) could introduce a change in dose from À12% to 24%. The large biases revealed by this study suggest that consistent absorbed dose calculation approaches are essential when comparing 
